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Abstract: Research on milk fat globule membrane (MFGM) is gaining traction. The interest is two-fold;
on the one hand, it is a unique trilayer structure with specific secretory function. On the other hand,
it is the basis for ingredients with the presence of phospho- and sphingolipids and glycoproteins,
which are being used as food ingredients with valuable functionality, in particular, for use as a
supplement in infant nutrition. This last application is at the center of this Review, which aims to
contribute to understanding MFGM’s function in the proper development of immunity, cognition,
and intestinal trophism, in addition to other potential effects such as prevention of diseases including
cardiovascular disease, impaired bone turnover and inflammation, skin conditions, and infections as
well as age-associated cognitive decline and muscle loss. The phospholipid composition of MFGM
from bovine milk is quite like human milk and, although there are some differences due to dairy
processing, these do not result in a chemical change. The MFGM ingredients, as used to improve
the formulation in different clinical studies, have indeed increased the presence of phospholipids,
sphingolipids, glycolipids, and glycoproteins with the resulting benefits of different outcomes
(especially immune and cognitive outcomes) with no reported adverse effects. Nevertheless, the
precise mechanism(s) of action of MFGM remain to be elucidated and further basic investigation
is warranted.
Keywords: milk fat globule membrane; polar lipid composition; sources; production; clinical studies;
infant nutrition; infant formula
1. Introduction
Breastfed infants have a lower incidence of all-cause and infection-related mortality than their
bottle-fed counterparts [1]. Human milk (HM) provides the newborn with the nutrients (proteins,
long-chain fatty acids, carbohydrates, vitamins, minerals, etc.) and immune protection (antibodies
and oligosaccharides) needed to promote optimal growth and development. Among many other
important components of HM, an increasing body of evidence shows that the milk fat globule
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membrane (MFGM) and its constituents support the education and development of the immune
system of infants [2–6], which is attributed to both the presence of cholesterol and polar lipids,
including phospho- and sphingolipids, and to the abundance of glycosylated and non-glycosylated
proteins. Because MFGM can exert diverse positive health effects on immune and GI outcomes,
brain development, gut functionality, metabolism, and cognition, as reported in human and animal
studies [7–9], it seems appropriate to think that the addition of MFGM to infant formula (IF) could
bring the product closer to approximating HM composition and function.
MFGM is a complex structure made of lipid droplet buds originating from the endoplasmic
reticulum of lactocytes, forming a phospholipid monolayer vesicle that helps emulsify lipids in the
aqueous cytoplasm. As the lipid droplets reach the apical cell membrane, an additional bilayer from
the lactocyte plasma membrane encases the fat droplet during extrusion from the cell [10]. Therefore,
MFGM is structurally composed of a triple layer of phospholipids and cholesterol with incorporated
proteins and glycoproteins and it maintains the physical, chemical, and functional characteristics of
the apical surface membrane of the mammary epithelial cells from which it originates.
Research on MFGM has been gaining momentum due to (1) its unique trilayer structure and
composition, namely the presence of phospho- and sphingolipids and glycoproteins; (2) the search for
novel supplements/nutraceuticals and bioactive ingredients to be employed in several circumstances;
and (3) the opportunity to source MFGMs in large amounts at quite low prices. Indeed, there are two
areas where MFGM could be conceivably exploited. The first one is infant nutrition because formula-fed
infants have much lower intakes of MFGM than breastfed ones [11]. This lower MFGM intake is
due to the replacement of milk fats with vegetable oils in IF. The addition of MFGM to IFs allows for
the provision of nutrients that play important roles in neural and cognitive development. Examples
of these nutrients include gangliosides, sialic acid, and sphingomyelin. Further, these molecules
contribute to the proper development of immunity and intestinal trophism, possibly mediated by
the evolving microbiota. The second area where MFGM is being positioned is the prevention of
several diseases including cardiovascular disease [12], impaired bone turnover and inflammation [13],
skin conditions [14], and infection by E. coli [15], as well as age-associated diseases such as cognitive
decline and muscle loss. Stemming from the observation that the phospholipid composition of MFGM
is quite similar to that of neuronal cell membranes, some investigators are proposing the use of MFGM
to counteract the loss of some neuronal components such as polyunsaturated fatty acids (PUFAs),
namely those of the omega-3 series [16–19].
In view of the aforementioned increasing relevance of MFGMs, this review focuses on the human
(namely infant) and animal research that collectively suggests that MFGM and its components show
efficacy on different aspects of human health. In particular, we focus on the risk–benefit of using
ingredients enriched with MFGM or milk phospholipids in IF [20].
2. Sources, Production, and Treatments of Dairy-Based Ingredients Containing Milk Fat Globule
Membrane (MFGM)
The potential use of MFGM to design emulsions for dairy products and IFs has been reviewed by
several authors over the last decade [4,21–28]. MFGM structure and function characteristics are still
not fully elucidated; however, a number of technological approaches to obtain MFGM isolates or to
generate MFGM-enriched dairy ingredients have been brought to commercial scale and the use of
these ingredients as supplements for IFs or other MFGM-enriched products is now feasible.
Dairy-based ingredients containing MFGM fragments including minor lipids fall in two categories,
namely MFGM-enriched ingredients and phospholipid extracts [29]. MFGM-enriched ingredients
are obtained by a combination of physical processes, whereas most of the phospholipid extracts
are obtained by solvent extraction from MFGM-enriched fractions [30]. Phospholipid extracts do
not contain MFGM fragments and instead are used in cosmetic and skin-care applications, whereas
MFGM-enriched ingredients are better designed for nutritional applications.
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Destabilizing the milk fat globule natural emulsion is at the basis of most of the commercial
processes to produce MFGM-enriched ingredients [31,32]. As illustrated in Figure 1, cream that is
obtained by skimming whole milk constitutes the raw material for butteroil or anhydrous milk fat
(AMF) and butter manufacturing. Beta serum and buttermilk, the co-products of these two dairy foods,
contain most of the MFGM components, including minor lipids and MFGM proteins. Cheese whey,
the co-product from cheesemaking processes, is also considered a potential source of MFGM-enriched
ingredients since it contains residual fat mainly composed of milk minor lipids and MFGM proteins.
This fat must be removed from the whey feed before the valorization of whey proteins as whey protein
concentrates (WPC) or whey protein isolates (WPI). The phase inversion obtained by churning of a fat
cream generates butter grains mainly composed of triacylglycerol (TAG) together with buttermilk,
an aqueous phase having an overall composition similar to that of skim milk but also containing
MFGM constituents. Buttermilk downstream processing can simply consist of evaporation and spray
drying, but membrane separation processes can be applied in order to increase the protein and MFGM
content of the MFGM-enriched powder.
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powdered ingredients.
MFGM-enriched ingredients can also be obtained by additional two methods. One method occurs
during the AMF production process, after destabilization of concentrated cream in which the fat
content of cream is raised from 35–45% to 75% by centrifugal separation and the cream concentrate is
then fed to a homogenizer where phase inversion occurs. This process produces a >99.5% fat phase
and an aqueous phase called beta serum that contains all of the MFGM components. The second
method involves melting and holding butter at 60 ◦C f r 30 min, followed by centrifugal separation
leading to a >99.5% fat oil phase and an aque us phase of buttermilk containing MFGM constituents.
As mentioned earlier, another source of MFGM is cheese whey by-products. Cheese whey typically
contains 0.5–0.8% protein, 4.5–5.0% lactose, and 0.1–0.5% residual fat. The fat level is highly dependent
on the (standardized) cheese milk composition and on the characteristics of the cheesemaking process.
The residual fat found in cheese whey is mainly composed of minor lipids and free fatty acids, although
some small droplets of TAG released from the cheese matrix can occur in whey. Downstream whey
processing aims at recovering and purifying whey proteins as functional ingredients by ultrafiltration
(UF) and/or microfiltration (MF) and, for this purpose, the whey feed must be defatted prior to
membrane processing i order to prevent membrane fouling. Whey cream can be generated by classical
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centrifugal separation; however, complete defatting of whey is advised for downstream ion-exchange
chromatography in the manufacture of WPI. Such defatting can be achieved using thermo-calcic
aggregation that consists of the addition of CaCl2 and pH adjustment [33,34]. The aggregates generated
by this process can be collected by a soft stream separator or by milk fat (MF) processing. In both cases
the aggregated phase contains a higher proportion of MFGM constituents. Whey processing also offers
the possibility to tailor MFGM-enriched ingredients with higher whey protein contents.
Several alternative methods or approaches to prepare MFGM-enriched ingredients developed
at laboratory or pilot scale have been reviewed [26,28,35–37]. Although these methods offer some
interesting features, their scale-up is often limited by technological or economic considerations.
Among these alternative methods, washing the cream, i.e., diluting and re-concentrating the cream
by centrifugation is still considered promising from the point of view of MFGM yield [38]; however,
the performance is not well documented. Another approach is to process whey cream into whey butter
and buttermilk. In the latter case, the membrane-based concentration process to derive MFGM is
facilitated by the absence of casein micelles in whey buttermilk [39,40].
Some dairy ingredients manufacturers have developed proprietary processes to produce
MFGM-enriched ingredients and a relatively wide array of ingredients (in terms of composition) can
be found on the international market. Table 1 summarizes the overall compositional characteristics of
commercial MFGM-enriched ingredients currently available and prepared from co-products of butter,
anhydrous milk fat, or cheese whey. These ingredients not only differ from each other in terms of
overall composition (protein, lactose, ash, total lipids, and phospholipids), but the proportion of each
type of phospholipid is also different. Beta serum appears to be the ingredient offering the highest
phospholipid content (≥16%) in contrast with buttermilk, which has the lowest content (1.6%). MFGM
whey offers the possibility of providing up to 73% protein while still containing 7.5% phospholipids.
This high protein content represents an interesting feature in the context of nutritional products such
as IF or other dairy products. The detailed protein composition of MFGM-enriched ingredients is not
systematically disclosed in technical data sheets; however, most the ingredients prepared from cream,
beta serum, or buttermilk contain measurable amounts of gangliosides, MFGM proteins, cholesterol,
sialic acid, IgG, and lactoferrin [41–45].
Table 1. Commercially available MFGM-enriched dairy ingredients.
MFGM-Enriched Ingredients
(g/100 g Product) Buttermilk Beta Serum Whey
Source/process Butter Anhydrous milk fat Cheese whey
Protein (N × 6.38) ≥30 >52 73
Lactose ±50 ≤10 ≤3
Ash ≤9 ≤6 ≤3
Total lipids 5–13 3–27 12–26
Total phospholipids (PL) (g/100g fat) 1.6–22 ≥14 5–16
Phospholipids (% of total PL)
- Phosphatidyl ethanolamine (PE) 35–43 22–29 19–41
- Phosphatidyl choline (PC) 19–32 27–47 19–25
- Phosphatidyl serine (PS) 8–18 1.2–23 8–12
- Phosphatidyl inositol (PI) 4–9 1–8 3.6–7
- Sphingomyelin (SM) 11–19 14–27 16–24
- Others - <4 <7
Moisture ≤4% ≤5% ≤6%
pH 6.0–6.5 6.2–6.8 6.4
Average lipid composition based on refs. [29,35,37,46].
The ingredients listed in Table 1 describe the major differences in compositional characteristics
according to the source of MFGM. It must be emphasized that each category of ingredient can be
tailor-made accordingly to meet the end-user specifications. The ingredients manufacturer can adjust
the composition of the final ingredients by process control (centrifugation speed and temperature,
UF/MF concentration, etc.). Several studies have shown that the polar lipid profile of MFGM-enriched
Nutrients 2020, 12, 1607 5 of 25
streams from buttermilk, butter serum, or MFGM whey can be modified by adjusting technological
conditions [37,47–52]. Finally, the approach of blending different feeds (for example, beta serum,
WPI, other milk solids) can also lead to tailored MFGM-enriched ingredients for specific applications,
such as IFs.
3. Biological Effects of MFGM
The composition, health attributes, and biological activity of commercial ingredients containing
MFGM, milk phospholipids, or MFGM isolated in the laboratory have been extensively
reviewed [2,5,22,25,53–59]. Given the complexity of the composition of MFGM, here we present
in a differentiated way the available information on health benefits of (a) proteins and (b) lipids,
in particular phospholipids.
3.1. Proteins of the MFGM
The main proteins associated with the MFGM from its genesis in lactation have been identified
and all of them have been sequenced by identification of their genetic code. Table 2 summarizes such
proteins and their molecular weights.
Table 2. Proteins native to the MFGM.
Protein Common Name Molecular Weight
BRCA1 and BRCA2 210
Mucin I (MUC1) 160–200





PAS 6/7 (lactadherin) 47–59
Proteose peptone 3 18–34
FABP 13–15
BRCA: Breast Cancer proteins; PAS: Protein domain; FABP: fatty acid-binding protein.
There are several aspects that must be underscored: (1) All proteins are glycosylated except ADPH
and FABP, which are also of smaller molecular weight, and (2) in general, there are other important
proteins associated with MFGM. Butyrophilin and XDH/XO constitute about 40% and 12% of total
MFGM proteins, respectively, and mucins are highly sialylated proteins, with about half of their weight
made up of carbohydrates. These proteins are in milk and, whether by methodology of isolation or
by natural affinity, they are generally present in any laboratory or industry concentration or isolation
of MFGM proteins. Whey proteins, especially beta-lactoglobulin, lactoferrin, and immunoglobulins,
are commonly associated with MFGM [60,61]. Therefore, it is important to consider the method of
isolation and a detailed composition of the ingredient used to study the properties of MFGM (as
described in the previous section).
Table 3 summarizes the studies that support some of the health benefits of the MFGM proteins (as
individually studied related to their biological activity).
Table 3. Biological studies of MFGM proteins (Adapted from ref [58]).
Component Health Aspects References
Studies in vitro and in vivo
Mucin I (Muc1)
Antiadhesive effect [62]
Protective effect against rotavirus infection [63,64]
Effects on digestion [65]
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Table 3. Cont.
Component Health Aspects References
Xanthine dehydrogenase/ Antimicrobial agent [66]
oxidase (XDH/XO) Source of reactive oxygen species(ROS)/anti-inflammatory properties [67]
Butyrophilin (BTN)
Suppression of multiple sclerosis [68]
Development of experimental autoimmune
encephalomyelitis [69]
Influence on pathogenesis of autistic behavior [70]
Regulation of immunity [71]
Periodic acid Schiff 6/7 (PAS 6/7)
(lactadherin)
Protection from viral infections in the gut [63,72]
Epithelialization, cell polarization, cell movement
and rearrangement, neurite outgrowth, synaptic
activity in the central nervous system
[73]
Fatty acid binding Breast cancer cells lines inhibition [74–76]
Protein (FABP) Association with breast cancer; indicator [77–80]
Cluster of differentiation (CD36)
Anticancer properties by interacting with FABP [75]
Anti-inflammatory properties [54]
Breast cancer susceptibility proteins
(BRCA1 and BRCA2) Breast cancer DNA repair process inhibition [81,82]
MFGM proteins (complex)
Prevention of diarrhea and improvement of anemia [7]
Retroviral infection prevention [83]
Lipid digestion and cholesterol absorption reduction [55]
Proteomic studies of MFGM in their
complexity
Association and correlation studies with health or
nutrition [84]
Comparative study of human and cow proteins [85]
3.2. Lipids of the MFGM
To date, there are still many MFGM lipid components in both human and bovine milk that
continue to be further investigated in terms of their structure, function, role, and biological significance
to human health. Examples of such components are glycerophospholipids (as phosphatidylcholine
(PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and
sphingolipids (especially sphingomyelin, SM)), glycolipids (cerebrosides and gangliosides), cholesterol,
and other minor components [86]. The MFGM polar lipids (phospho- and sphingolipids) account
for 60–70% of total milk polar lipids and their concentration (about 20 mg/100 mL) is comparable
between human milk fat and bovine milk fat [87–90]. Of the major lipids present in MFGM, SM is
perhaps best understood as contributing to neurodevelopment and thus is of particular interest for
MFGM supplementation in infant formula milk. The range of mean SM concentrations in HM has
been reported from 24.5–174 mg/L [91–96]. The phospholipids present in IF are based on vegetable fat
and are generally provided by lecithin derived from either sunflower seeds or soybeans [97]; however,
SM and PS cannot be sourced via plant-based fat blends and must be sourced from bovine milk.
Among the structural functions of MFGM, its ability to stabilize the MFG as an emulsion that
facilitates its digestion, absorption, and metabolism stands out as a novel property since it facilitates
bioaccessibility and bioavailability of naturally occurring bioactive components in MFGM [18,98].
Milk polar lipids can be found both in MFGM (which accounts for the largest quantity) and in
nanovesicles that are secreted into milk by the mammary gland cells and are implicated in cell-to-cell
communication by means of their functionally active cargo (such as mRNA, miRNA, and different
proteins) [2].
While it is very difficult to find studies on MFGM that completely discriminate its components,
many investigations on the topic focus on the phospholipids [2,99–102]. One factor unifies these
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studies—the conclusion that the health benefits of MFGM lipids build the grounds for their inclusion
in functional foods.
3.3. Preclinical Evidence on MFGM Components and Ingredients
As we consider the efficacy of MFGM and its biological activity, it is important to understand
the characteristics of the ingredients used for experimentation. As discussed above (and in Table 1),
MFGM ingredients can derive from different starting materials. MFGM ingredients are largely similar
to more commonly used dairy ingredients (buttermilk, WPC), with the main difference being that they
have a much higher concentration of phospholipids and proteins originating from MFGM. In part
due to its heterogenous composition, MFGM indeed has multiple mechanisms of action by which
it improves human health. The predominate mechanisms that have been studied in infant health
are: anti-pathogenic (both through decoy or direct bactericidal activity); modulation of the intestine,
mucosal immune system, and gut microbiota; and neurodevelopment. A thorough description of these
mechanisms has been recently reviewed [103]. A brief description of each follows and within Table 4
descriptions of preclinical studies on MFGM ingredients can be seen.
Table 4. In vivo evidence on MFGM ingredients for brain, intestine/immune, and microbiome
development (adapted from ref [103]).
Ingredient Description Model Design Primary Finding Ref





Improved Novel Object and
Morris Water Maze performance [104]
CML-Beta serum
concentrate (BSC) Young rats
Provided orally from PD10–60
as a gelatin
Reduced latency in Morris Water
Maze test; increased expression of




(MFGM-10 Lacprodan ®) Rat pups
Oral supplementation MFGM
ingredient at 500 mg/kg BW
until PND21
Improved neurodevelopment
(increased gene expression of
BDNF and glutamate-receptor)















(MFGM-10 Lacprodan ®) Rat pups
MFGM via cannulas inserted
into the stomach
Brain metabolite differences along
with improved reflexes (ear and




(MFGM-10 Lacprodan ®) Rat pups
MFGM in combination with
prebiotics and subjected to
stress via maternal separation
Ameliorated stress-induced
visceral hypersensitivity and







Mixture of lactoferrin, MFGM
ingredient, and polydextrose
galacto-oligosaccharides
(PDX/GOS) for 30 days
T microvascular changes in the
brain related to grey matter
concentration and diffusivity
within the internal capsule
[110]
Whey-derived MFGM
(MFGM-10 Lacprodan ®) Piglets
Milk replacer with 0, 2.5, or 5
g/L of MFGM ad libitum access
Higher serum cholesterol and
HDL in MFGM-2.5 g/L; No




Nutrients 2020, 12, 1607 8 of 25
Table 4. Cont.
Ingredient Description Model Design Primary Finding Ref
MFGM and immune/intestinal development
Sweet buttermilk
powder MFGM Rats
Buttermilk powder enriched in
food pre- and during infection
Reduced colonization and




MFGM incorporated into diet
for a period of 12 weeks; colon
carcinogenesis rat model
Provided resistance to gut insult
through significantly less aberrant
crypt foci
[113]
Cream-derived MFGM Mice MFGM into diet for 5 weeksand injected with LPS
More resilient to intestinal
inflammation, lower levels of




(MFGM-10 Lacprodan ®) Neonatal mouse
MFGM ingredient daily
during suckling period and
treated with a
lipopolysaccharides challenge
on postnatal day 21
Less inflammation (lower
inflammatory cytokines, GI hist




(MFGM-10 Lacprodan ®) Rats
MFGM ingredient from day
2–14 post operation 75–85%
small bowel resection









two concentrations in a model
of Necrotizing enterocolitis
(NEC)
Higher concentration group (12
g/L) exhibited reduced intestinal













(increased enzyme activity and
morphology) and lower
pathogenic bacteria in the colon
[118]





Mixture of MFGM, lactoferrin,
and prebiotics in a stress
model
Improvements in sleep and




(MFGM-10 Lacprodan ®) Rat pups
MFGM in combination with




(MFGM-10 Lacprodan®) Rat pups
Formula with MFGM via
cannulas inserted into the
stomach’ challenged with C.
difficile toxin
MFGM protective against C.






PL-20 was compared with soy




PL showed significantly higher
relative abundance of multiple
bacteria and concentrations of












Lutispora, and Sutterella, which




undescribed source Neonatal piglet
Formula with MFGM
fragments compared with milk
fat and with vegetable oils
MFGM had increased
Proteobacteria and Bacteroidetes and
decreased Firmicutes; changes in




Anti-pathogenic effects of MFGM may derive from either direct bactericidal activity or interference
with pathogen adhesion to the intestinal epithelium (decoy effect), thus preventing these pathogens
from either access into the body or the initiation of physiologic cascades leading to adverse effects
such as infection-induced diarrhea and inflammation. There is a large body of literature investigating
how MFGM and its components may reduce the burden of common infectious diseases including:
Escherichia coli [15,123–129], Salmonella enteritidis [112,124,130,131], Listeria monocytogenes [112],
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and rotavirus [132,133]. These studies provide evidence that direct binding to and inhibition of GI
pathogens by MFGM can occur within the gut lumen and are consistent with the absence of evidence
for MFGM-related toxicity.
• Intestinal epithelial, mucosal immune system, and gut microbiota
In addition to direct interactions with GI pathogens, MFGM and its components have also
been studied for their effects on gut immune, microbial, and epithelial development. The potential
contributions to the infant immune system by MFGM and its individual components, such as lactadherin
and gangliosides, have been reviewed [5]. The most commonly reported immune modulatory effects
consist of shifts in balance favoring anti-inflammatory over inflammatory cytokines [134–136], providing
protection from inflammatory damages within the intestine [114–117,137], and modulating the gut
microbiome [109,118–122,138,139]. The role of MFGM in modulating the microbiome is still currently
an ongoing discussion, as many of the studies cited have multiple nutritional interventions (other
prebiotics or different fat sources). Nonetheless, these studies support the addition of MFGM to IF in
order to support the gut and immune development of infants.
• Neurodevelopment
Building upon the observation that there has historically been a gap in some cognitive outcomes
between breastfed and formula-fed infants, a variety of preclinical studies have provided evidence for
the mechanisms by which MFGM components, specifically polar lipids and sialic acid, and ingredients
support the development and proper functioning of the central nervous system [140–148]. All the
publications support the addition of MFGM to IF in order to provide long-lasting cognitive benefits
and narrow the gap between formula fed and breastfed infants.
In summary, the literature on MFGM-enriched ingredients has been shown in multiple preclinical
model systems to demonstrate consistent support for normal brain, immune, and gut development
function (Table 4.).
4. Comments on Clinical Studies
As we reported previously [2], the structure and composition of different ingredients containing
MFGM vary widely, as shown in Figure 2.
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Figure 2. Electron microscope image of three different commercial ingredients containing MFGM. Each
sample varies in composition and concentration of phospholipids and in structure. However, all of
them have been used successfully in food products all over the world (adapted from ref [2]).
In Table 5 we provide a summary of all the clini al trials on MFG and its components for infants
and young children. How ver, given the variety in structure and omposition of MFGM ingredients,
we consider it important to focus i detail on some of the reported clinical studies on cognitive
development and other measures for a single ingredie t defined as WPC e riched with MFGM. Several
Nutrients 2020, 12, 1607 10 of 25
double-blind controlled trials have investigated safety, growth, neurodevelopment, and health/adverse
event outcomes in infants and young children consuming the WPC-MFGM ingredient. In line with the
findings from animal studies, the studies we review below have demonstrated that such consumption is
safe, well tolerated, and lacks evidence of adverse effects to growth, cognition, behavior, gastrointestinal
health, or immunity. In fact, where differences have been found between MFGM-fed groups and control
groups, they have supported the potentially beneficial outcomes of consuming supplemental MFGM.
Table 5. Summary of clinical research studies on MFGM and its component for infants and young
children. * MFGM is classified into various types depending on its source or the bioactive components:
ganglioside enriched (GNGL), phospholipids, whey protein concentrate (WPC), complex milk lipids
(CML), and sphingomyelin (SM).
MFGM Type * Methods Results Safety Study
GNGL
Preterm infants (32–36 weeks)
fed IF with added
gangliosides (GMF, n = 20)
(1.43 mg/100 kcal) compared
to (–) gangliosides (MF, n = 20)
for 4 weeks
Reduced levels of Escherichia
coli in the feces of GMF
compared to MF at postnatal
day 7; higher fecal counts of
Bifidobacteria at postnatal day
30 in GMF





IF provided to preterm infants
+/– added PLs (+n = 34)
(–n = 85) in the hospital;
development of NEC was
observed
Infants fed PL formula
developed less NEC stage II
and III with similar rates of
bronchopulmonary dysplasia,
septicemia, and retinopathy of
prematurity.
None: No difference in weight





fed daily for 6 months to
infants aged 6–11 months
(5.9 g/day) (n = 253); skim milk
control (n = 246)
Lower prevalence of diarrhea
(3.8% MFGM vs. 4.4% skim);
46% reduction of episodes of
bloody diarrhea
None: No difference in growth
or serum markers (ferritin,
zinc, or folate) were observed.
[7,150]
GNGL CML
IF with GNGL enriched CML
(n = 29) fed to healthy infants
(2–8 weeks old) until six
months old; compared to
non-supplemented formula
(n = 30) and BF reference
group (n = 32)
Test group had increased
behavioral test scores on the
Griffiths Mental Development
Scale at 6 months.
None: No differences in
growth or tolerance between
the two formula groups.
[151]
SM
IF with SM (n = 12) or control
(n = 13) fed for 8 weeks to low
birth weight infants (<1500 g);
evaluations up to 18 months
Increased SM in total PLs and
improved scores on Behavior
Rating Scale of the BSID-II, the
Fagan test scores, the latency
of visual evoked potentials,
and sustained attention test
scores at 18 months





Supplement 2 g CML + 3 g
whole-milk power or control
5 g whole-milk powder for
12 weeks to infants age
8–24 months
Lower duration of rotavirus
diarrhea and prevalence of
major illness in the CML
group was observed.
None: There were no





MFGM-10 at 6g/L (n = 80),
standard formula (n = 80), and
BF reference group (BF)
(n = 72) fed to term infants




cognitive domain scores vs.
the control group at 12 months
of age; overall phenotypes
observed to be more similar to
BF group
None: No difference in
eczema or any skin rash
reported. MFGM formula
supported growth and was
well tolerated. Lower
incidence of otitis media and
antipyretic drug use reported.
Serum antibody levels were
more similar to BF group.
[154–158]
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Table 5. Cont.
MFGM Type * Methods Results Safety Study
WPC
IF supplemented with
MFGM-10 (n = 72), MFGM-L
“lipid rich” (n = 70), or SF
control (n = 57) fed to infants
≤14 days old at enrollment
and provided until 4 months
of age.
No significant differences
were found for plasma PLs,
cardiolipin, cholesterol ester,
IGF-1, or leptin. No
differences were observed in
polio or HiB antibodies, with
the exception of lower mean
polio virus type 1 IgG level in
the MFGM-10 in one group.
No differences were found




No difference in adverse
events or growth and
tolerance. However, post-hoc
analysis reported rates of
eczema were higher in
MFGM-10® group (13.9% vs.
3.5% in SF). The short duration
and relatively small sample
size, as well as the unequal
allocation of subjects among
groups, which may have




IF supplemented with MFGM
concentrate compared to
control formula and BF
reference from <2 months of
age and 2 months of
consumption.
Concentration of serum LDL
and cholesterol in MFGM-fed
infants was comparable to the
BF reference group.
None: No adverse events were
reported. [160]
CML MFMG
IF with MFGM (n = 226) fed to
full term infants <14 days old
up to 12 months and
compared to BF reference
group (n = 206).
Growth and dropout rate had
similar scores between FF
infants and BF reference at
birth and 6 months.
Behavioral tests, serum GNGL,
and gut microbiota were
measured.
None: No differences in





IF containing either goat milk
fat/plant oil mixture (GIF) or
control formula with only
plant oil fat provided to
healthy infants up to 4 months
of age.
Significantly different SM and
fatty acids patterns were
observed between groups.
However, the profiles did not
directly represent the dietary
fatty acid pattern.
None: No differences between
groups in weight gain or
adverse events was observed.
[162]
WPC
IF, SF with MFGM-10 or with
probiotic (L. paracasei ssp.
paracasei strain F19) along with
a BF reference group (n = 200
per group) fed for 4 months
and followed to 12 months.
MFGM formula group did not
have significantly more
diarrhea, fever, days with
fever, clinic visits, or URI
episodes than the other
formula groups or the BF
infants.
None: Both experimental
formulas were well tolerated
and supported normal growth.
Adverse event rates were
highest in the control formula
group with significantly more
fever episodes and days with




IF provided 2 weeks through
12 months with either SF (n =
208) or MFGM-10 at 5 g/L with
Lactoferrin (0.6 g/L (n = 198).
Children were followed to 18
months of age.
MFGM+Lf formula group had
higher cognitive, language,
and motor Bayley-III scores at
12 months, better sustained
attention at 12 months, and
higher scores on some
elements of language
performance at 18 months,
and were not inferior to the
control group in any
neurodevelopmental measure.
None: No significant
differences between groups in
growth, intolerance, fussiness,
or stool characteristics were
observed. Adverse event
analysis demonstrated no
differences between groups in
antibiotic use and significantly
lower incidences of GI and
respiratory adverse events
(including diarrhea, URI, and
cough) for the MFGM + Lf






IF added MFGM-10, GNGL,
LC-PUFA’s, sialic acid, and
synbiotics (n = 85) compared
to a control formula (n = 85)
and BF reference group (n =
50). Term infants fed from <2
months of age until 18 months.
There were no differences in
growth or neurodevelopment
between formula groups;
however, visual function was
found to be more similar to
the BF reference group.
None: No difference in
weight/length gain between
formula groups was observed.
[164]
In 2011, Zavaleta et al. reported the effects of an MFGM-enriched complementary food on health
outcomes in older infants, enrolling 499 primarily breastfed term infants between 6 to 11 months of
age [7]. Results showed no differences between groups in growth or serum markers (anemia, ferritin,
zinc, or folate). Furthermore, the group receiving MFGM had a significantly lower prevalence of
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diarrhea vs. the control group (3.8% vs. 4.4%), as well as a significant reduction (46%) in episodes of
bloody diarrhea.
Several follow-up publications have been made in response to the Zavaleta study. A recent
follow-up publication on this trial demonstrated specific metabolome and immune-related outcomes in
infants who consumed MFGM. These infants (6–11 months of age) displayed a decreased Th1 response
that was attributed to lowered serum cytokine IL-2. Thus, this study further corroborates the immune
outcomes found in the trial as the Th1 immune system is activated during infection [150]. In another
study, Gurnida et al. (2012) studied the effects of formula supplemented with a ganglioside-enhanced,
MFGM-derived, complex milk lipid in term infants [151]. Healthy infants (2–8 weeks) were fed until
6 months of age with either standard control IF (n = 30) or a supplemented IF (n = 29) with added
MFGM-derived lipids to increase total ganglioside concentration from 6 to 9 mg/100 g. The measured
level of gangliosides in the supplemented formula fell within the range reported for HM. A breastfed
reference group (n = 32) was also included. There were no differences in any growth parameter
between the two formula groups. There were no differences in reported morbidities between the two
formula groups, including symptoms such as fever and cough, diarrhea, allergy, vomiting, or colic.
There were also no adverse effects on developmental milestones; conversely, the test formula group had
increased scores on three domains of the Griffiths Mental Development Scale at 6 months compared to
the control group and did not significantly differ from the breastfed reference group.
A study with slightly older children, 2.5 to 6 years old was reported by
Veerman-Wauters et al. [165]. In this trial, the children consumed a fortified milk beverage (in
addition to usual diet) for a period of four months. The control group beverage (n = 97) contained
60 mg/day of endogenous phospholipid, while the test group beverage (n = 85) contained a total of
500 mg/day of phospholipid due to the addition of MFGM concentrate. Both beverages were reported as
well-tolerated with no differences in symptoms or health outcomes between groups. The questionnaire
for evaluating safety and potential problems included rash, vomiting, diarrhea, constipation, cough,
varicella, otitis, pharyngitis, doctor visits, days of school absence, or use of medication. Statistically
significant reductions were found only for days with fever and number of short febrile episodes
(<3 days), both in favor of the MFGM-supplemented group. The primary outcome, the validated
Achenbach behavioral-emotional assessment questionnaire (ASEBA), was completed by parents and
teachers; the only significant difference found was lower behavioral problem scores, as determined by
parent assessment, in favor of the MFGM group.
There is also a study that focused on the safety and tolerance of MFGM when added to IF [159].
This trial investigated growth and tolerance in healthy term infants receiving standard control formula
(n = 57) or formula enriched with a protein-rich MFGM fraction (MFGM ingredient, n = 72) or a
lipid-predominant MFGM fraction (MFGM-L, n = 70) up to 4 months of age [159]. Growth and
formula tolerance did not differ between groups. Overall incidence of adverse health events or serious
adverse health events did not differ statistically between groups, except for post hoc testing reporting
a higher rate of eczema in the MFGM ingredient-fed group (13.9% vs. 3.5% in control and 1.4%
in MFGM-L). The authors recognized limitations to the interpretation of this finding, concluding:
“Although...adequately powered to evaluate non-inferiority...with respect to weight gain, limitations of
the study for investigating other outcomes include its short duration and relatively small sample size,
as well as the unequal allocation of subjects among groups, which may have introduced some degree
of bias between the control and the experimental groups”. It is also observed that for several other
reported events, incidence was lower in the MFGM-ingredient group including otitis media (2.1-fold
lower) and oral candidiasis (6-fold lower), though these did not reach statistical significance.
Perhaps the most important and highly cited papers on this topic are the two published by
Timby et al. in 2014 and 2015. These studies aimed to determine the effects of supplementation
with MFGM on growth, health, and cognitive outcomes [154,156]. Term infants (<2 months old)
were assigned to consume either a standard formula (n = 80) or an MFGM-supplemented formula
(n = 80) until 6 months of age. The investigational formula contained MFGM-10 at a dose of 6 g/L.
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A breastfed reference group (n = 72) was also included. Results demonstrated that growth, tolerance,
and safety were equivalent between formula groups. Comparison of adverse events, disease symptoms,
and medication use demonstrated that the incidence of acute otitis media during the intervention was
significantly decreased in the MFGM group compared to control (1% vs. 9%), and not significantly
different from the breastfed reference group (0%). No other differences in other infections or health
outcomes were seen; in particular there was no significant difference in incidence of eczema or any skin
rash (17% in the MFGM group vs. 26% in control). The only difference in medication use was lower
antipyretic drug use in the MFGM group. Serum anti-pneumococcal IgG titers were measured as a
secondary endpoint. Of 10 measured serotypes, the MFGM group had lower concentrations for types 1,
5, and 14 compared with the control group, though the authors note that for all serotypes pneumococcal
titers were also lower in the breastfed reference group than in the control formula. Furthermore, it can
be observed that for 8 of 10 serotypes, mean antibody levels in the MFGM group are closer than the
control group to breastfed infant levels. Cognitive assessment at 12 months of age with the Bayley-III
Scales showed significantly higher mean cognitive domain scores in the MFGM-fed group vs. the
control group, with no significant differences in the four other developmental domains, demonstrating
that there was no evidence for adverse effects to either health or neurodevelopmental outcomes.
Investigations into the cardiometabolic profile [155], oral microbiome [157], the fecal microbiome and
metabolome [166], serum metabolome [166], and serum, plasma, and erythrocyte lipidome [167] have
additionally been described.
The latest papers that have an in-depth study and large number of subjects are those from
Li, X. et al. [9] and Li, F. et al. [163]. The first study evaluated the effects on growth and infectious
outcomes of IF supplemented with either MFGM or a probiotic (L. paracasei ssp. paracasei strain
F19) [9]. A total of 600 infants were randomized to consume either a standard control formula, formula
supplemented with MFGM-10, or formula with probiotic (n = 200 per group) for 4 months. A breastfed
reference group was also recruited (n = 200), and all infants were followed until one year of age.
Both experimental formulas were well tolerated and supported normal growth. Adverse event rates
were highest in the control formula group. Overall, during the intervention, the MFGM-formula group
did not have significantly more diarrhea, fever, days with fever, clinic visits, or upper respiratory
infection (URI) episodes than the other formula groups or the breastfed infants. In contrast, the control
formula group (without MFGM) had significantly more fever episodes and days with fever than the
breastfed reference group.
A separate study was designed to evaluate the growth, health, and cognitive effects of formula
containing both MFGM and lactoferrin (Lf) [163]. Healthy term infants were fed through 12 months
with either routine control formula (n = 208) or a formula containing MFGM-10 at 5 g/L + lactoferrin
0.6 g/L (n = 198). Unlike prior studies, children were followed to 18 months of age after finishing the
study formula consumption at 12 months. Results showed no significant differences between groups
in growth, tolerance, stool characteristics, or antibiotic use; the MFGM+Lf group had significantly
lower incidences of GI and respiratory adverse events (including diarrhea, URI, and cough) compared
to the control group. Again, there were no differences in reported incidence of skin events or eczema,
notably in a study with a much larger population size and longer follow-up period than the Billeaud
2014 study. Finally, cognitive outcome measures showed that the MFGM+Lf formula group had higher
cognitive, language, and motor Bayley-III scores at 12 months, longer sustained attention at 12 months,
and higher scores on some elements of language performance at 18 months compared to the control
formula group.
In summary, the body of clinical studies to date that test the dietary effects of an MFGM-enriched
diet in infants and young children have consistently shown that the diets are well-tolerated and support
normal growth, health, and neurodevelopmental outcomes. The studies summarized here included
over 1000 children assigned to MFGM supplementation. Seven of these studies [7,9,155,156,159,161,165]
initiated feeding with MFGM-enriched formula at <2 months of age, and five [7,157,159,167] used the
same source of MFGM ingredient. Though the majority of studies were designed to follow health and
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safety outcomes to endpoints of 12 or 18 months, the longest-term follow-ups to date from MFGM
feeding in infancy now extend to 6 and 13 years of age [11]. Overall, this collective clinical evidence
strongly supports the safety of MFGM supplementation in the infant and young child populations
and has not highlighted specific concerns for adverse pediatric outcomes. Indeed, the data is more
consistent with beneficial effects of consuming supplemental MFGM as compared to formulas with
only inherent amounts of MFGM.
5. MFGM-Enriched Dairy Ingredients: Critical Unit Operations and Safety Concerns
All commercial MFGM-enriched dairy ingredients are manufactured from regular dairy products
(butter, cream, or cheese) or from their by-products. The processing approach for the manufacture of
MFGM-enriched dairy ingredients involves two categories of unit operations, namely: (i) Physical
processes: churning, pressure-driven membrane separation (UF or MF), centrifugal separation
(skimming or concentrating cream), and (ii) Operations involving heating: high temperature/short
time (HTST) pasteurization, sterilization, evaporative concentration, spray-drying. Other operations
involving the use of chemical additives such as CaCl2 for defatting cheese whey can also be involved,
but this substance does not represent safety concerns since it is already used in most of the cheese
manufacture processes that generate cheese whey.
All dairy ingredient manufacturers must implement procedures such as the Hazard Analysis
Critical Control Point (HACCP) procedures to avoid any product microbial or chemical contamination
of the ingredients. Heat-treatments such as pasteurization (72–75 ◦C/16 s) and other HTST heat
treatments (for example, 115–135 ◦C/20 s to 2 min.) are the most important critical control points with
regards to product safety in ingredients manufacture [29]. Typical MFGM-enriched dairy ingredients
must meet microbial specifications in terms of standard plate count (<10,000/g), Enterobacteriaceae
(neg/g), Salmonella (neg/750 g), Bacillus cereus (<100/g), and yeast and mold (<200/g). However,
additional contaminant microorganisms (such as Cronobacter) may be included as specification from
the perspective of using these ingredients in IFs.
6. Regulatory and Safety Aspects of Infant Formula (IF) Added Ingredients
In recent years, IF manufacturers have added ingredients such as omega-3 PUFAs and probiotics
to their products. These innovations have created new regulatory challenges. Some algorithms are
being proposed and the fast pace at which new bioactive compounds are being introduced to the
market indeed calls for action [168].
According to the FDA, approximately one million infants in the United States are fed IF from
birth and by three months of age about 2.7 million infants rely on IF as part of their nutrition. Of note,
the agency does not approve IFs before they can be marketed. In June 2014, the FDA issued the final
rule “Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification
Requirements, and Records and Reports for Infant Formula,” which requires manufacturers of IF to
use current good manufacturing practices specifically designed for IF. In addition, producers must
test for the presence of noxious microbes such as Salmonella and/or Cronobacter, demonstrate that their
IFs support physical growth and that the protein component is of adequate biological quality (this
quality is based on Regulations under Sections 201(s), 201(z), and 412 of the Federal Food, Drug and
Cosmetic Act), and test IFs for nutrient content before they put it on the market and again at the
end of the product’s shelf life. The new formula must be notified to the FDA at least 90 days before
being commercialized.
In Europe, the Commission mandates the European Food Safety Authority (EFSA) to assess
the safety of xeno-ingredients added to foods, granting the Novel Food status to constituents of
proven safety at habitual levels of intake [169,170]. The legal framework is that of Regulation (EU)
2015/2283 (25 November 2015) of the European Parliament and of the Council on Novel Foods and the
Commission Implementing Regulation (EU) 2017/2469. The overarching goal is that of an EFSA project
on a customer-oriented approach for regulated products aiming at supporting applicants and other
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stakeholders during the whole life cycle of the applications for regulated products. The aforementioned
document includes a completeness checklist that the applicant first and the EFSA later use to verify the
completeness of the data for risk assessment in the technical dossier [170]. Four summary tables are
also included for applicants to summarize the results of the scientific studies provided in the technical
dossier. As regards IF, they are covered by Commission Directive 2006/141/EC and its subsequent
amendments. As of 2021, IF will be regulated by Commission Delegated Regulation (EU) 2016/127,
which is built on the observation that “Infant formula is the only processed foodstuff which wholly
satisfies the nutritional requirements of infants during the first months of life until the introduction of
appropriate complementary feeding.” This regulation specifically mentions omega-3 PUFAs and their
minimum and maximum amounts.
In Australia, the Food Standard Australia New Zealand (FSANZ) authority regulates novel foods
in a manner similar to the EFSA one. Of note, in Australia and New Zealand, novel foods and novel
food ingredients are regulated under Standard 1.5.1-Novel Foods in the Food Standards Code. A novel
food cannot be sold as food or used as a food ingredient unless it is listed in that Standard, which is
continuously amended.
As far as MFGMs are concerned, to the best of our knowledge, there is only one published, small
sample size, non-inferiority trial [159] that evaluated a lipid-rich MFGM concentrate (MFGM-L) and a
protein-rich MFGM concentrate (MFGM-P) versus standard formula. In post-hoc analysis, the authors
reported a higher (13.9%) rate of eczema in the MFGM-P group compared to the control (3.5%) and
MFGM-L (1.4%) groups. The authors commented that their findings should be interpreted with caution
and, as noted previously, no increased risk of eczema or rash were demonstrated in two subsequent
larger and longer-term feeding studies using the same source (MFGM-10) at equivalent levels [8,9].
A possible interpretation for this discrepancy might be the current lack of a systematic eczema scoring
system, which is being developed [171]. In other words, eczema is usually assessed based on parental
reports, daily records, and physician examinations, which are not standardized. In addition, the lipid
component of MFGMs is, conceivably, devoid of side effects even though some authors suggest an
adjuvant effect based on uncertain biological mechanisms [172]. Conversely, the protein component of
MFGMs could be implicated in some allergic reaction, although there are no clear indications of such
an effect.
In summary, while the existing clinical data generally support the safety and, in several regards,
the benefits of supplementing MFGM in infants and young children, the current lack of harmonization
between various regulatory frameworks as well as the relatively limited number of human trials targeted
at both effectiveness and safety of MFGM impede us from drawing firm conclusions. Additional
well-designed, large-scale future trials will be necessary in order to fill the gaps in knowledge about
MFGM and to provide more definitive evidence for safety.
7. Future Developments
MFGM-enriched ingredients are now available for use in IFs. Further research should address the
processing of these MFGM enriched ingredients, including:
• Better characterization of minor MFGM proteins and their content along with their variability,
as influenced by the processing conditions of the ingredients.
• Demonstrate and ensure that MFGM systems deliver bioactivities to the infants in a reproducible
manner (process control vs. variability of raw material).
• Develop sustainable processes as alternatives to solvent extraction to increase the phospholipid or
minor lipid content from MFGM-enriched ingredients.
In terms of clinical investigations, though evidence to date has been promising, there remains a
need for further randomized trials with well-defined neurocognitive and safety endpoints in order to
better understand the effects of supplemental MFGM in infant feeding. Given the essential role of
appropriate infant nutrition to health and development throughout childhood and beyond, such studies
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merit attention from researchers, public health bodies, and funding agencies. Furthermore, when
considering the variety of other potentially bioactive molecules present in human milk including
oligosaccharides, lutein, and other carotenoids, it is possible to consider that these may work additively
or synergistically with MFGM to provide benefits [18].
8. Conclusions
In this Review we arrive at the following conclusions: the source for MFGM in all the studies
presented has its origin in bovine milk, and although there are some differences in processing, the final
composition of MFGM ingredients is within a limited range where the phospholipids present in
the ingredients are very similar to the composition of these in milk. The literature also shows that
the processing involved in concentrating the different ingredients does not result in a chemical
change—these processes result in concentration of the components originally found in native MFGM
of bovine milk. The ingredients, as used to improve the formulations used in all the different studies,
have indeed increased the presence of phospholipids, sphingolipids, glycolipids, and glycoproteins,
with the resulting benefits of different outcomes (especially immune and cognitive) sought in the various
studies. However, although there are remarkable and measurable benefits, the precise mechanism that
leads to these benefits remains to be elucidated. One aspect that seems to be evident is that there are
no reported adverse effects that would increase the health risk of using these ingredients.
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